Mark Salvati

Mark Salvati is currently the Vice President Global Program Head for Translational and Clinical Oncology at Regeneron, where they lead the development of Anti-LAG3 Antibody Fianlimab and Anti-GITR Antibody programs. Throughout their career, they held significant roles at companies such as Amgen and Janssen Inc., contributing to the development of Immuno-Oncology portfolios and therapies. Mark earned a Ph.D. in Organic Chemistry from the University of California, Los Angeles, enhancing their expertise in the field. Their prior experience includes leadership roles in medical affairs and clinical research across several prominent pharmaceutical companies.